Completed

Phase Not Applicable
Age: 18Years - 45Years
All Genders
ID00000897

The Effect of Oral and Injectable Contraceptives (Norethindrone/Ethinyl Estradiol, Medroxyprogesterone Acetate) and Gender on Plasma and Intracellular Zidovudine Pharmacokinetics

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2011-03-02

42

Participants Needed

6

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to look at the effects of different methods of birth control (oral and injectable) on how the body absorbs, makes available, and removes zidovudine (ZDV). This study will also evaluate the differences in men and women in how the body absorbs, makes available, and removes ZDV. Past research has shown that the effectiveness of ZDV as an anti-HIV drug might be decreased in individuals who use certain methods of birth control. ZDV may also have different effects in men compared to women.

CONDITIONS

Official Title

A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women

Who Can Participate

Age: 18Years - 45Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

Inclusion Criteria

Men and women may be eligible for this study if they:

  • Are HIV positive.

Women may be eligible for this study if they:

  • Have regular periods and a normal gynecological exam, (including a Pap smear and mammogram).
  • Enter the study between Days 10 and 18 of the first day of their last period.
  • Are willing to use either the Pill or Depo-Provera as birth control.
  • Have a negative pregnancy test within 14 days prior to study.

Exclusion Criteria

Men and women will not be eligible for this study if they:

  • Cannot take ZDV for any reason.
  • Have cancer.
  • Are taking stavudine.

Women will not be eligible for this study if they:

  • Cannot take the Pill or Depo-Provera.
  • Are pregnant or nursing.
  • Are receiving nelfinavir and want to enroll in Step 2.
  • Have a history of chronic high blood pressure, thrombophlebitis, and/or pulmonary emboli if participating in Step 2 of the study.

(This study has been changed so that women with certain criteria are excluded from participating in Step 2.)

Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

Trial Site Locations

Total: 6 locations

1

San Francisco AIDS Clinic / San Francisco Gen Hosp

San Francisco, California, United States, 941102859

Status Unknown

2

Univ of Florida Health Science Ctr / Pediatrics

Jacksonville, Florida, United States, 32209

Status Unknown

3

Children's Hosp at Albany Med Ctr

Albany, New York, United States, 12208

Status Unknown

4

SUNY / Erie County Med Ctr at Buffalo

Buffalo, New York, United States, 14215

Status Unknown

5

Univ of North Carolina

Chapel Hill, North Carolina, United States, 275997215

Status Unknown

6

Univ of Washington

Seattle, Washington, United States, 98104

Status Unknown

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

TREATMENT

Number of Arms

0

Similar Trials

ACTION HIV: A Global Record of Anal Squamous Cell Carcinoma ...

Anal Squamous Cell Carcinoma

Actively Recruiting

1 location

Long-term Follow-up Study of HIV-infected Individuals in HIV...

HIV Infections

Actively Recruiting

1 location

Evaluation of Oral VH4524184 with Emtricitabine and Tenofovi...

HIV Infections

Actively Recruiting

113 locations

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here